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The  Immunophenotype  of Splenic  Lymphoma  With  Villous  Lymphocytes  and 
its  Relevance  to  the  Differential  Diagnosis  With  Other  B-Cell  Disorders 
By  Estella Matutes, Ricardo Morilla,  Kwasi Owusu-Ankomah, Angela Houlihan, and Daniel Catovsky 
Splenic  lymphoma  with villous  lymphocytes  (SLVL)  is  a 
low-grade disorder that regularly  presents  with peripheral 
blood involvement. We  describe the immunophenotype  of 
the circulating  cells  from  100  SLVL patients  whose disease 
has  been  characterized  on  clinical,  morphologic,  and  histo- 
logic  grounds.  Cells  from  all  cases  expressed  B-cell  anti- 
gens (CD1  9 and CD37) and/or  HLA-Dr and  showed light 
chain  restriction  (./X:  1.5/1)  with  moderate to strong inten- 
sity  of  membrane  lg staining.  Cells  from  most  cases 
(>  80%) were  CD24+,  FMC7+,  and  expressed  strongly 
membrane  CD22.  The  monoclonal  antibodies  CD10, 
CD23, and CD38 were positive  in one-third of the cases; 
CD1 IC  in 47%; and CD25 in 25% of  cases.  A minority  of 
cases ( <  20%) were positive with  HC2, B-ly-7, and CD5. 
PLENIC  LYMPHOMA  with  villous  lymphocytes 
(SLVL) is a recently recognized low-grade non-Hodg- 
kin's lymphoma with distinct clinical and morphologic fea- 
tures that include splenomegaly, lymphocytosis rarely ex- 
ceeding 100 X  109/L, and a discrete monoclonal  band  in 
the serum.'"  The circulating cells have condensed nuclear 
chromatin with a small nucleolus and exhibit  characteristic 
short and  thin cytoplasmic villi.  Cells with lymphoplasma- 
cytic differentiation are common in peripheral blood films 
and  other  affected tissues. SLVL has been regarded as a  sub- 
type of lymphoplasmacytic lymphoma5 and described un- 
der  a variety of designations such as  malignant lymphoma 
simulating hairy cell leukemia (HCL)6,7  or splenomegalic 
immunocytoma with circulating hairy cek5  SLVL cases 
have probably been included  in  series describing CD  1 l c+ B 
cells with intermediate  features  between chronic lympho- 
cytic leukemia (CLL) and HCL'  or reported  as  a  special 
group of  CLL.9 A  monoclonal  B-cell lymphocytosis with 
circulating CD1 1  c+  villous lymphocytes but  no  organomeg- 
aly has also been reported as an early form of SLVL." 
SLVL could be misdiagnosed as CLL, particularly the 
splenomegalic form,  HCL  or its variant form (HCL-vari- 
ant),  and  B-cell  prolymphocytic  leukemia  (B-PLL). Al- 
though SLVL has been well characterized as  a  distinct en- 
tity,'.4*'I  there  is  little  information  on  its  membrane 
phenotype, particularly with the B-cell markers  B-ly-7,'2213 
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However, none  of the 19  CD5+  cases had the phenotype 
characteristic of  chronic  lymphocytic  leukemia  (CD5+, 
CD23+,  FMC7-, weak surface lg and  membrane CD22). 
None  of the 17  CD25+ cases had the immunophenotype 
typical of hairy  cell  leukemia  (CD25+,  CD1 IC+,  HC2+,  B- 
ly-7+).  HC2  and B-ly-7 were the most  useful  reagents to 
distinguish  SLVL  from  hairy  cell  leukemia.  Our  findings 
demonstrate that SLVL has  a distinct immunologic  profile 
and  that  monoclonal  antibodies  are  important  for  the 
differential  diagnosis  between this  disease  and  other  B- 
lymphoproliferative  disorders  with which SLVL can be con- 
fused. 
0  1994 by  The American  Society  of Hematology. 
CD1  CD22, and CD23, which are important in the 
differential diagnosis between SLVL, HCL, and CLL. 
We describe here the immunologic profile in 100 cases of 
SLVL using an extensive panel of  monoclonal  antibodies 
(MoAbs) and compare  the  findings with those of other B- 
lymphoproliferative  disorders to examine whether  SLVL 
has a distinct immunophenotype  that  can  be useful for the 
diagnosis of this disease. 
MATERIALS  AND  METHODS 
Patients.  Samples from  100 patients with SLVL studied in our 
laboratory between  1983 and 1992 have been analyzed. These  in- 
cluded  57 males and 43 females with a median age of 68 years 
(range, 24 to 89). All had lymphocytosis (>5  X  109/L)  with more 
than 20% villous cells. The diagnosis was based on clinical features, 
peripheral  lymphocyte morphology (Fig  l), and histology of the 
bone  marrow  (48 cases), spleen (42 cases), and/or lymph  nodes  (10). 
May-Griinwald-Giemsa-stained peripheral  blood  films were  re- 
viewed in all cases by two of us (D.C. and E.M.) and classification 
was based on  the  French-American-British (FAB) criteria? 
lmmunologic markers.  Peripheral blood mononuclear cells iso- 
lated  by  density  gradient  centrifugation  with Lymphoprep  (Ny- 
comed, Oslo, Norway) were analyzed in 94 cases. In 6 other cases, 
studies were performed  on cell suspensions from the spleen ob- 
tained by finely mincing  the tissue and sieving and separating the 
mononuclear cells. 
Cells were washed three  times  in Hanks' Balanced Salt Buffer So- 
lution before immunologic staining. A panel of B- and T-cell mark- 
ers  and  fluorescein isothiocyanate-conjugated (FITC) goat  anti- 
mouse lg F(ab)*  fragment (Cappel, Durham, NC) as a second layer 
was  used  by  indirect  immunofluorescence.  The specificity and 
source of the MoAbs is given in Table l.  To  avoid nonspecific bind- 
ing to the Fc-y receptors, 2% pooled human AB serum was added 
to the  buffer  throughout  all the steps. Analysis was performed on  an 
FACScan flow cytometer (Becton Dickinson, Mountain View, CA) 
using a lymphocyte gate. In some cases in which light chain restric- 
tion was not  shown by  FACS, the  immunoalkaline  phosphatase 
antialkaline  phosphatase  (APAAP)  technique16 with  anti-r  and 
anti-X reagents was applied on cytocentrifuge-made slides. Controls 
were set up by replacing the  MoAb with a mouse Ig of  the  same 
isotope. A marker was considered positive when expressed in  more 
than 30% of cells above  the  control.  In a few cases in which the 
proportion of circulating SLVL cells was less than 40%  a cut-off 
point  of 20% was used. The proportion of T lymphocytes was esti- 
mated by the expression of CD2. 
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Fig 1.  Peripheral  blood  film 
from  an  SLVL  case  showing 
lymphocytes with  short  cyto- 
plasmicvilli. 
Surface Igs (Smlgs) were investigated by  direct  immunofluores- 
cence using RTC  goat anti-r  and  anti4  polyclonal  antibodies  (Cap 
pel)  and  FITC  rabbit  anti-Ig  heavy chain  antibodies  (Dakopatts. 
Glostrup,  Denmark).  Before staining  with  antihuman Ig, the cells 
were incubated  for 30 minutes in medium  at 37°C to  remove  het- 
erophilic antibodies: the  buffer  used in  all  the  steps did  not  contain 
AB  serum. The  intensity  of  Igexpression  wasestimated  by  FACS  in 
a histogram  data  display selecting the log scale in the fluorescence 
axis  and  geometric  statistics. A weak reaction (+/-) was considered 
to occur  when  the  positive  peak was within the first  logarithmic 
percentile, moderate (+) when it  was within  the  second, and  strong 
(++ or  +++)when the peak was within  or  more  than  three percen- 
tiles of  the negative control. 
Table 1. MoAbs  Used  in This Study 
CD or 
Specificity  MoAb  Source 
CD2 
CD5 
CD1  0 
CD1 1c 
CD1  9 
CD22 
CD23 
CD24 
CD25 
CD37 
CD38 
HLA-DR 
Nonclustered 
Nonclustered 
Nonclustered 
RFTl1 
UCHT2 
J5 
Leu-M5 
RFB9 
OKB22 
MHM6 
L30 
anti-11-2 
WR17 
OKTl  0 
GRBl 
FMC7 
B-ly-7 
HC2 
Prof G. Janossy (London,  UK) 
Prof P. Beverley  (London,  UK) 
Coulter  (Hialeah,  FL) 
Becton Dickinson  (Mountain  View, CA) 
Prof G. Janossy (London,  UK) 
Ortho (Raritan,  NJ) 
Prof  D.  Crawford (London,  UK) 
Dr K. Kikuchi  (Sapporo,  Japan) 
Becton Oickinson (Mountain  View, CA) 
Prof  J.L. Smith (Southampton,  UK) 
Ortho (Raritan,  NJ) 
Prof F. Garrido Torres (Granada) 
Sera-Lab  (Crawley  Down, Sussex,  UK) 
Dr S.  Poppema  (Ontario,  Canada) 
Dr  D. Possnett (New  York,  NY) 
RESULTS 
A variable  proportion  of cells (30%  to 90%) from  all  cases 
expressed at  least  one of the  B-cell antigens (CD  19, CD37, 
and/or class I1 HLA determinants)  and  all  showed  clonality 
by Ig light  chain  restriction  (Table 2).  The intensity of SmIg 
fluorescence  intensity  was  strong  to very strong  in  56% of 
cases, moderate  in  32%. and  weak  in  12%.  Ig heavy chains 
were investigated  in 45 cases. Of these, 14 cases (3  l%) were 
IgM and IgD, 9 (20%)  had IgM only, and 9 (20%)  were IgG. 
Less common patterns  were IgG and IgM (4 cases). IgD (3 
cases), IgA (3  cases). and  undetectable  (3  cases). 
Table 2. Membrane  Markers  in 100  Cases of SLVL 
No. of Cases 
Marker  Tested  Positive  Positive Cases 
Percentage of 
Smlg 
K 
x 
CD22 
CD24 
FMC7 
CD1 lc 
CD1 0 
CD23 
CD38 
CD25 
CD5 
B-ly-7 
HC2 
100 
100 
75 
55 
98 
60 
77 
71 
50 
69 
100 
41 
46 
60 
40 
71 
49 
87 
28 
23 
24 
15 
17 
19 
6 
4 
60 
40 
95 
89 
89 
47 
30 
31 
30 
25 
19 
15 
9 
All cases were CD1  9'.  CD37'.  and/or HLA-Dr+. 1560  MATUTES ET  AL 
Table 3. ComDarison With CLL Markers in 19 CD5+  Cases 
No. of Cases 
Fig 2.  FACS  profile of SLVL  cells  showing  strong  expression of 
FMC7 and CD22 and negative  expression of CD5 and CD23. 
Findings with the various MoAbs are  summarized  in  Ta- 
ble 2. Cells from the majority of cases were CD22+,  CD24+, 
and FMC7'.  The expression of membrane CD22 was strong 
in 8  1% ofthe cases and weak in  the rest (Fig 2). CD1 IC  was 
positive in 47% of cases; CDIO, CD23, and CD38 were pos- 
itive in one-third of cases; CD25 was positive in 25% of 
cases; and CD5, B-ly-7, and HC2 were positive in less than 
2070 of cases. The proportion of cells staining with CD5 in 
the CD5-  SLVL cases paralleled the findings with  CD2. 
Two cases  were  CD2'.  In these 2 cases, there was overlap 
between the expression of CD2 (7 1  % and 66% positive cells) 
and B-cell markers (8  1%  and 8470 positive cells). Both of 
these cases were CD5'. 
The findings in the 19 CD5+ SLVL cases were compared 
a- 
~~~~~ 
CD23  11  3 
!=MC7  17  14 
CD22+'+'  16  12 
Srnlg 
Weak  18  3 
Moderate to strong  18  15 
with  those  of  markers that  are  usually positive (CD23), 
weakly expressed (SmIg, mCD22), or negative (FMC7) in 
CLL (Table 3). Most of them were  FMC7'  and expressed 
SmIg (Fig 3) and CD22 strongly; only 3 of 18 had weak SmIg 
and CD23 was positive in less than one-third of  cases.  None 
of these CD5+ SLVL had the phenotype characteristic of 
CLL (CD5+,  CD23+,  SmIg+/-,  CD22- or +'-,  FMC7T). 
Table 4 summarizes the findings with three HCL markers 
(B-ly-7, HC2, and CD1 IC) in the 17 CD25'  SLVL  cases. 
No single case was HC2'  and only I coexpressed B-ly-7 and 
CD25; the cells in the latter case were HC2- and CD1 IC-. 
No  single case  had  the  typical  marker  profile  of  HCL 
(CD1  IC',  CD25',  HC2'.  B-ly-7+)  (Fig 4). 
DISCUSSION 
The classification and precise characterization of chronic 
lymphoproliferative disorders is based on several parame- 
ters that include cell morphology, histopathology, and im- 
munologic  Immunophenotyping plays a ma- 
jor diagnostic role by distinguishing B- from T-cell disorders 
and by defining immunologic profiles characteristic of some 
7 "  4 
Marker  Tested  Posltlve 
Fig 3.  Comparison of the fluorescence intensily 
of Smlg in (A)  SLVL  and  (B) CLL. IMMUNOPHENOTYPE OF  SLVL 
diseases such as CLL and HCL. There is little information 
on  the  immunologic profile of SLVL, a recently recognized 
disorder. We have analyzed here the  immunophenotype  of 
the circulating cells in a large series of patients to  see whether 
immunophenotyping  helps to distinguish SLVL from other 
B-cell lymphoproliferative diseases. Our study showed that 
in approximately 80%  of  cases, the marker profile of SLVL 
is moderate to strong  SmIg  and CD22, FMC7+ and CD24+, 
and CDY,  HC2-, and B-ly-7-.  These findings are therefore 
different from those seen in CLL and HCL cells. 
A recent review  of our  data  on 400 CLL patients shows 
that, in  contrast to SLVL, cells from  more than 75% of the 
cases express weak SmIg and  are  CD5+ and CD23'  in  more 
than 90% of cases, whereas strong expression of FMC7 and 
membrane CD22 are rare. Although a minority of SLVL in 
our series were CD5+,  the immunologic profile of such rare 
cases was clearly different from that of CLL, when consider- 
ing other B-cell  markers (Table  3).  CD23  was  less  useful 
than CD5 to discriminate between CLL and SLVL because 
it was positive in  one-third  of  the latter cases. This is not 
surprising because the expression of CD23, but not CD5, 
has been shown in  lymph nodes in 56% of lymphoplasma- 
cytic lymphomas"  and 30%  of non-CLL  condition^.^' 
When a comparison between the phenotypes  of SLVL 
and HCL was made, we also found  major  differences. Some 
of the markers  characteristic  of HCL, such  as  B-ly-7  and 
HC2,I3x2O  were rarely positive in SLVL and, although a small 
proportion  were  HC2+ or  B-ly-7+, none  of  them coex- 
pressed  these  markers.  Unlike  HC2 and B-ly-7, the two 
other  markers  usually  positive  in  HCL,  CD25  and 
CD1 lc,14315  were also positive in 25%  to 47% of SLVL cases. 
One report on  the  immunophenotype  of HCL described the 
expression of CD  1 IC in 4 cases that could have been classi- 
fied as SLVL.21  Within SLVL cases that were CD25+,  28% 
were also CD1 IC+,  whereas none was HC2'  and only  l 
coexpressed B-ly-7. Therefore, HC2 and B-ly-7 are the two 
HCL markers  more  useful to distinguish SLVL from HCL. 
A  diagnostic  problem  may  sometimes  arise  between 
SLVL and  the  variant form of HCL."  From this  study and 
our previous study, it is apparent  that there may be some 
overlap between the markers of SLVL and HCL-variant. 
However, there are subtle differences that may be helpful in 
the differential diagnosis between these two conditions  in 
cases with borderline morphology. Thus, CD1 IC  and B-ly-7 
are more often positive in the HCL variant (100% and 40%, 
respectively) than in SLVL (47% and  15%,  respectively), 
whereas CD24 and CD25 are,  as  a rule, negative in the HCL 
variant and positive in 89%  and 25%  of SLVL cases, respec- 
tively. 
Table 4. Comparison With HCL Markers in 17 CD25+ Cases 
No. of Cases 
Marker  Tested  Positive 
HC2  16  0 
CD1 lc  11  3 
B-ly-7  12  1' 
This case was CD1 1  c- and HC2-. 
1561 
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Fig 4.  FACS  profile  of an  SLVL  case  positive  with  CD25  and  neg- 
ative with  HC2  and B-ly-7. 
Although a comparison between the immunologic profile 
of SLVL with that of other B-cell NHL with lymphocytosis 
was not the main purpose ofthis analysis, our  data  show that 
there are also some differences with mantle cell lymphoma, 
which is almost always CD5'.  With the markers used in  this 
study,  there  is no good evidence for the existence of a differ- 
ent immunologic profile in SLVL and follicular lymphoma. 
In  summary,  we have shown that SLVL has an  immuno- 
logic profile distinct from that of CLL and HCL that could 
therefore  be useful for the differential diagnosis between 
these B-cell disorders. A precise diagnosis of these condi- 
tions is relevant because of the implications for manage- 
ment because it is apparent  that  SLVL patients  can benefit 
mainly from splenectomy:  whereas they are poorly respon- 
sive to alkylating agents or a-interferon, agents used for the 
treatment of CLL and HCL, respectively. There is no infor- 
mation so far on  the  efficacy in SLVL of the new agents, 
2' deoxycoformycin and 2' chlorodeoxyadenosine, currently 
used in HCL. 
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